Spots Global Cancer Trial Database for temozolomide
Every month we try and update this database with for temozolomide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin | NCT00993044 | Refractory Soli... | Irinotecan Vincristine Temozolomide Bevacizumab | 12 Months - 20 Years | Children's Hospital Los Angeles | |
| Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases | NCT00238251 | Lung Cancer Metastatic Canc... | gefitinib temozolomide radiation thera... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma | NCT06279767 | Glioblastoma Cancer Temozolomide | 6-mercaptopurin... | 18 Years - 65 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT02337426 | Adult Brain Gli... Adult Giant Cel... Adult Gliosarco... | Dimethyl Fumara... Temozolomide Radiation Thera... | 18 Years - | Virginia Commonwealth University | |
| Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | NCT05685004 | Glioblastoma Mu... | TVI-Brain-1 Standard of Car... Radiotherapy Temozolomide | 18 Years - 80 Years | TVAX Biomedical | |
| VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma | NCT00516282 | Brain and Centr... | CLORETAZINE temozolomide | 18 Years - | Northwestern University | |
| Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00482677 | Brain and Centr... | temozolomide DNA methylation... quality-of-life... Radiation | 65 Years - 120 Years | Canadian Cancer Trials Group | |
| Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide | NCT00250211 | Glioblastoma Glioma | Functional MRI ... | 18 Years - 65 Years | AHS Cancer Control Alberta | |
| Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT) | NCT05634707 | Primary Brain T... Brain Tumor, Re... | Fluoxetine Temozolomide | 24 Years - | Duke University | |
| Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | NCT01009515 | Melanoma | Paclitaxel, car... | 18 Years - | New Mexico Cancer Care Alliance | |
| Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) | NCT03643549 | Glioblastoma | Bortezomib and ... Bortezomib and ... | 18 Years - | Haukeland University Hospital | |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | NCT02168270 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma Gliosarcoma | ascorbic acid temozolomide quality-of-life... laboratory biom... | 19 Years - | University of Nebraska | |
| Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma | NCT04091503 | Glioma, Maligna... Gliosarcoma Astrocytoma of ... | Intranasal Modi... | 21 Years - 70 Years | Center Trials & Treatment Europe | |
| Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | NCT00365222 | Glioblastoma Gliosarcoma | Temozolomide | 70 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide | NCT04945148 | Glioblastoma, I... | Metformin Radiation IMRT Temozolomide | 18 Years - | Hopital Foch | |
| Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors | NCT00137774 | Neuroendocrine ... | Bevacizumab Temozolomide | 18 Years - | Dana-Farber Cancer Institute | |
| Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma | NCT00200161 | Glioblastoma Gliomas | Temozolomide Temozolomide | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | NCT04324840 | Glioblastoma | CC-90010 Temozolomide Radiotherapy | 18 Years - | Celgene | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | NCT06346067 | Advanced or Met... | Naporafenib Dacarbazine Temozolomide Trametinib | 18 Years - 99 Years | Erasca, Inc. | |
| Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | NCT01182350 | Diffuse Intrins... | Bevacizumab Erlotinib Temozolomide Radiation | 3 Years - 18 Years | Dana-Farber Cancer Institute | |
| Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors | NCT00302159 | High Grade Glio... Brain Tumors | adjuvant therap... Temozolomide Valproic Acid Radiation thera... | 18 Years - 90 Years | National Institutes of Health Clinical Center (CC) | |
| ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00770471 | Brain and Centr... | temozolomide veliparib DNA methylation... gene expression... mutation analys... proteomic profi... high performanc... immunoenzyme te... laboratory biom... mass spectromet... pharmacogenomic... pharmacological... adjuvant therap... radiation thera... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00099125 | Brain and Centr... | irinotecan hydr... temozolomide adjuvant therap... radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors | NCT00547131 | Brain and Centr... Metastatic Canc... | temozolomide laboratory biom... liquid chromato... mass spectromet... pharmacological... conventional su... stereotactic ra... | 18 Years - 120 Years | City of Hope Medical Center | |
| Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT00916409 | Glioblastoma Mu... | NovoTTF-100A de... Temozolomide | 18 Years - | NovoCure Ltd. | |
| AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma | NCT04881032 | Glioblastoma | Polysiloxane Gd... radiotherapy Temozolomide | 18 Years - 75 Years | Centre Jean Perrin | |
| Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma | NCT02039778 | Glioblastoma Malignant Gliom... Brain Tumors Anaplastic Astr... | Stem Cell Radio... | 18 Years - 70 Years | Beth Israel Medical Center | |
| Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT) | NCT00311857 | Glioblastoma Mu... | Cetuximab Temozolomide Radiation thera... | 18 Years - 70 Years | Heidelberg University | |
| Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults | NCT01043536 | Glioblastoma | radiotherapy temozolomide | 18 Years - 70 Years | Centre Georges Francois Leclerc | |
| Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma | NCT05694416 | MGMT-Unmethylat... | Etoposide Plus ... | 18 Years - 70 Years | Zhongnan Hospital | |
| Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | NCT00365222 | Glioblastoma Gliosarcoma | Temozolomide | 70 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma | NCT03927222 | Glioblastoma | Human CMV pp65-... Temozolomide Tetanus-Diphthe... GM-CSF 111-Indium-labe... | 18 Years - | Duke University | |
| Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery | NCT04316039 | Low-grade Gliom... | Temozolomide intensity modul... | 18 Years - 70 Years | West China Hospital | |
| A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma | NCT03880019 | Stage III Uteri... Stage IV Uterin... Uterine Corpus ... | Computed Tomogr... Core Biopsy Magnetic Resona... Olaparib Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma | NCT00005951 | Brain and Centr... | irinotecan hydr... temozolomide | 18 Years - | Duke University | |
| CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy | NCT00257205 | Melanoma | dacarbazine CP-675,206 temozolomide | 18 Years - | AstraZeneca | |
| Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas | NCT04122911 | Neuroendocrine ... | Temozolomide | 18 Years - | National Cancer Institute, Naples | |
| Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | NCT03197506 | Glioblastoma Gliosarcoma Supratentorial ... | External Beam R... Laboratory Biom... Pembrolizumab Radiation Thera... Temozolomide Therapeutic Con... | 18 Years - | Mayo Clinic | |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | NCT05417594 | Advanced Solid ... | AZD9574 Temozolomide [11C]AZ1419 339... Datopotamab Der... Trastuzumab Der... | 18 Years - 130 Years | AstraZeneca | |
| Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00047294 | Brain and Centr... | celecoxib temozolomide thalidomide adjuvant therap... | 18 Years - 120 Years | Dana-Farber Cancer Institute | |
| Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma | NCT05739942 | Newly Diagnosed... | [177Lu]Lu-NeoB [68Ga]Ga-NeoB Temozolomide | 18 Years - | Novartis | |
| Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00047294 | Brain and Centr... | celecoxib temozolomide thalidomide adjuvant therap... | 18 Years - 120 Years | Dana-Farber Cancer Institute | |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | NCT00761280 | Anaplastic Astr... Glioblastoma | trabedersen temozolomide Drug delivery s... Placement of Dr... carmustine lomustine | 18 Years - 70 Years | Isarna Therapeutics GmbH | |
| A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma | NCT04900792 | Glioblastoma Glioblastoma Mu... | Ferumoxytol inj... Pharmacological... External beam r... Temozolomide | 18 Years - | University of Iowa | |
| Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children | NCT04532229 | Diffuse Intrins... | Nimotuzumab+CRT... | 3 Years - 15 Years | Biotech Pharmaceutical Co., Ltd. | |
| Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors | NCT00052780 | Childhood Centr... Childhood Choro... Childhood Crani... Childhood Epend... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Low-g... Childhood Medul... Childhood Mixed... Childhood Oligo... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... | O6-benzylguanin... temozolomide filgrastim pharmacological... laboratory biom... | - 21 Years | National Cancer Institute (NCI) | |
| Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | NCT00362570 | Oligoastrocytom... Anaplastic Olig... | Temozolomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | NCT05999994 | Neoplasms Child Adolescent | Ramucirumab Cyclophosphamid... Vinorelbine Gemcitabine Docetaxel Abemaciclib Irinotecan Temozolomide | 1 Year - 39 Years | Eli Lilly and Company | |
| Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer | NCT00003062 | Lung Cancer | temozolomide | - 69 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery | NCT04316039 | Low-grade Gliom... | Temozolomide intensity modul... | 18 Years - 70 Years | West China Hospital | |
| Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | NCT00662506 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | Cediranib Malea... Diffusion Tenso... Diffusion Weigh... Dynamic Contras... Fludeoxyglucose... Intensity-Modul... Laboratory Biom... Perfusion Magne... Positron Emissi... Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma | NCT01105702 | Brain Cancer | Temozolomide Bevacizumab Lithium Carbona... Radiation | 18 Years - | NYU Langone Health | |
| Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma | NCT02799238 | Glioblastoma | ALECSAT Radiotherapy Temozolomide | 18 Years - 70 Years | CytoVac A/S | |
| Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | NCT01465659 | Pancreatic Alph... Pancreatic Beta... Pancreatic Delt... Pancreatic G-ce... Recurrent Islet... | temozolomide pazopanib hydro... | 18 Years - | Northwestern University | |
| Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | NCT00597493 | Recurrent Gliob... | Sorafenib and T... | 18 Years - | Duke University | |
| Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors | NCT01141244 | Unspecified Chi... | temsirolimus temozolomide irinotecan hydr... laboratory biom... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Temozolomide in Treating Patients With Recurrent High-Grade Glioma | NCT00619112 | Recurrent Centr... | temozolomide | 18 Years - | University of California, San Francisco | |
| Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00021307 | Brain and Centr... | carboplatin temozolomide | 18 Years - | Fox Chase Cancer Center | |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | NCT04337177 | Solid Tumors Neuroblastoma Rhabdomyosarcom... Ewing Sarcoma Hepatoblastoma Medulloblastoma | VAL-413 Temozolomide | 1 Year - 30 Years | Valent Technologies, LLC | |
| Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme | NCT00458601 | Malignant Gliom... | CDX-110 with GM... Temozolomide | 18 Years - | Celldex Therapeutics | |
| Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma | NCT02046187 | Glioblastoma (G... | Ketogenic Diet Radiation thera... Temozolomide | 18 Years - 80 Years | St. Joseph's Hospital and Medical Center, Phoenix | |
| Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | NCT00039494 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | erlotinib hydro... 3-dimensional c... temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme | NCT02663440 | Glioblastoma Mu... | Hypofractionate... Granulocyte-mac... Temozolomide | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | NCT05432804 | MGMT-Methylated... Recurrent Gliob... Recurrent MGMT-... | Biospecimen Col... Magnetic Resona... Selinexor Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM | NCT03008148 | Glioblastoma | CCRT Temozolomide Siroquine | 20 Years - 80 Years | Johnpro Biotech, Inc. | |
| Dendritic Cell Cancer Vaccine for High-grade Glioma | NCT01213407 | Glioblastoma Mu... | Trivax, Temozol... Temozolomide, S... | 3 Years - 70 Years | Activartis Biotech | |
| Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00274833 | CNS Tumor, Adul... | erlotinib hydro... temozolomide radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors | NCT00786669 | Solid Tumor | Bevacizumab Temozolomide Vincristine Irinotecan Cefixime | 1 Year - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | NCT00612989 | Glioblastoma Gliosarcoma | Temodar and O6-... | 18 Years - | Duke University | |
| Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor | NCT01845675 | Advanced Well-d... | temozolomide or... | 18 Years - | Peking Union Medical College Hospital | |
| Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | NCT05685004 | Glioblastoma Mu... | TVI-Brain-1 Standard of Car... Radiotherapy Temozolomide | 18 Years - 80 Years | TVAX Biomedical | |
| Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma | NCT05694416 | MGMT-Unmethylat... | Etoposide Plus ... | 18 Years - 70 Years | Zhongnan Hospital | |
| Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma | NCT03927222 | Glioblastoma | Human CMV pp65-... Temozolomide Tetanus-Diphthe... GM-CSF 111-Indium-labe... | 18 Years - | Duke University | |
| Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III | NCT02761070 | Glioblastoma Recurrence Progression | Temozolomide Bevacizumab | 20 Years - 75 Years | Kyorin University | |
| Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | NCT00512798 | Brain and Centr... Melanoma Solid Tumor | PS-341 (VELCADE... temozolomide immunoenzyme te... PS-341 (VELCADE... Temozolomide | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | NCT01480479 | Glioblastoma Small Cell Glio... Giant Cell Glio... Gliosarcoma Glioblastoma Wi... | Rindopepimut (C... Temozolomide KLH | 18 Years - | Celldex Therapeutics | |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | NCT03197506 | Glioblastoma Gliosarcoma Supratentorial ... | External Beam R... Laboratory Biom... Pembrolizumab Radiation Thera... Temozolomide Therapeutic Con... | 18 Years - | Mayo Clinic | |
| A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor | NCT03204019 | Pancreatic Neur... | Tegafur and Tem... Tegafur and Tem... | 18 Years - | ChineseAMS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
